Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study
Authors:
- 8 September 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 46 (12) , 1088-1094
Abstract
The primary objective of this study was to investigate the safety and tolerability and to confirm the recommended dose of the anti-vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab in combination with docetaxel in Japanese patients with metastatic/locally advanced breast cancer. In this multicenter, single-arm, Phase Ib trial, eligibility criteria included: 20 years or older, Eastern Cooperative Oncology Group performance status of 0/1 and confirmed diagnosis of human epidermal growth factor receptor 2-negative metastatic/locally recurrent inoperable breast adenocarcinoma. Patients received docetaxel (75 mg/m 2 ) followed by ramucirumab (10 mg/kg) on Day 1 of 21-day cycles. Recommended dose was defined as 2 ) was confirmed as the recommended dose among Japanese patients, supporting its use in future studies.Keywords
This publication has 17 references indexed in Scilit:
- Cancer Incidence and Incidence Rates in Japan in 2008: A Study of 25 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) ProjectJapanese Journal of Clinical Oncology, 2014
- Vascular Endothelial Growth Factor Receptor-1 Expression in Breast Cancer and Its Correlation to Vascular Endothelial Growth Factor AInternational Journal of Breast Cancer, 2013
- Ramucirumab: A Novel Antiangiogenic AgentFuture Oncology, 2013
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Oncology, 2013
- An overview of the Japan Breast Cancer Research Group (JBCRG) activitiesBreast Cancer, 2013
- An Updated Report of the Trends in Cancer Incidence and Mortality in JapanJapanese Journal of Clinical Oncology, 2013
- Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast CancerJapanese Journal of Clinical Oncology, 2011
- Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2Current Oncology Reports, 2011
- Ramucirumab (IMC-1121B): A Novel Attack on AngiogenesisFuture Oncology, 2010
- A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerBritish Journal of Cancer, 1996